Live Breaking News & Updates on Cdr 132l

Stay informed with the latest breaking news from Cdr 132l on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Cdr 132l and stay connected to the pulse of your community

Novo nabs Cardior in €1B deal, gaining phase II-stage miRNA drug

In what co-founder and CEO Claudia Ulbrich called the “right decision with right partner at the right point in time,” Cardior Pharmaceuticals GmbH agreed to an acquisition by Novo Nordisk A/S in a deal worth up to €1.025 billion (US$1.1 billion) that puts a potentially disease-modifying heart failure candidate in the hands of a big pharma player in the midst of establishing its presence in cardiovascular disease.

Claudia-ulbrich , Novo-nordisk , Cardior-pharmaceuticals-gmb , Pharmaceuticals-gmbh , Novo-nordiska-s , Cardior-pharmaceuticals-gmbh , Cdr-132l , Heart-disease , Mir-132 , Mirna , Bioworld